Author Interviews, Personalized Medicine, Pharmacology / 16.11.2015
Cross Border Pharmaceutical Alliances Present Challenges and Opportunities
MedicalResearch.com Interview with:
Diane Frenier Esq
Reed Smith Corporate Partner
Member of Corporate & Securities Group and Life Sciences Health Industry Group
Background: Diane Frenier Esq discusses the M&A boom in the pharmaceutical and retail drug industry including a the "global study of 100 senior executives at life sciences companies by global law firm Reed Smith, in partnership with Mergermarket, reveals that 94% are planning to make an acquisition in the next year”.
Medical Research: What are the main drivers behind the pursuit of cross-border life sciences deals?
Ms Frenier: I think companies are trying to strengthen their capabilities in areas that are a core focus for them (e.g., in certain therapeutic areas, or for orphan drugs), and that includes adding products in those core focus areas and, in some cases, broadening geographically so they can market products in those core focus areas on a more global basis. This will allow them to use their resources more efficiently and take advantage of saving from reducing redundancies.
(more…)